PT - JOURNAL ARTICLE AU - Ikeuchi, Yusuke AU - Kohta, Masaaki AU - Yamashita, Shunsuke AU - Yamanishi, Shunsuke AU - Yamaguchi, Yoji AU - Tanaka, Jun AU - Tanaka, Kazuhiro AU - Kimura, Hidehito AU - Fujita, Atsushi AU - Hosoda, Kohkichi AU - Kohmura, Eiji AU - Sasayama, Takashi TI - Predicting Impaired Cerebrovascular Reactivity and Hyperperfusion Syndrome with BeamSAT MRI in Carotid Artery Stenosis AID - 10.1101/2024.01.02.24300743 DP - 2024 Jan 01 TA - medRxiv PG - 2024.01.02.24300743 4099 - http://medrxiv.org/content/early/2024/01/04/2024.01.02.24300743.short 4100 - http://medrxiv.org/content/early/2024/01/04/2024.01.02.24300743.full AB - Background We evaluated the impact of collateral flow of the middle cerebral artery (MCA) territory and cross flow visualized with internal carotid artery (ICA)-selective Magnetic resonance angiography (MRA) constructed by pencil beam presaturation (BeamSAT) pulse on preoperative cerebral hemodynamic status and postoperative hyperperfusion syndrome.Methods Fourty-eight patients who underwent carotid artery stenting or carotid endarterectomy were included. The preoperative status of collateral flow in the MCA territory and crossflow was assessed using ICA-selective MRA. Cerebral blood flow and cerebrovascular reactivity (CVR) were assessed using single-photon emission computed tomography. Potential signs of hyperperfusion syndrome (HPS) were retrospectively assessed by reviewing medical charts.Results Patients who either demonstrated mismatch in MCA signal intensity (MCA-MRA grade) between ICA-selective MRA by BeamSAT magnetic resonance imaging (MRI) and conventional MRA or whose MRA crossflow was visualized on BeamSAT MRI were placed in the developed collateral (DC) group (n=19). All other patients were placed in the undeveloped collateral (UC) group (n = 29). Preoperative ipsilateral CVR was significantly lower in the DC group than in the UC group (18.0±20.0% versus 48.3±19.5%; P<0.0001). Multivariate logistic regression analysis revealed that the DC group was significantly associated with impaired CVR (odds ratio [OR] = 17.7, [95%confidence interval [CI]: 1.82 to 171]; P = 0.013). The partial area under curves (AUCs) of BeamSAT logisitic model (0.843) were significantly larger than those of the conventional logistic model (0.626) over the range of high sensitivity (0.6-1) (p = 0.04). The incidence of postoperative symptoms suggestive of HPS was significantly higher in the DC group than in the UC group (8/19 vs. 1/29; P=0.001).Conclusions The differences in the MCA-MRA grade and crossflow between ICA-selective and conventional MRA were associated with impaired CVR. BeamSAT MRI may be a valuable and non-invasive tool for assessing of cerebral hemodynamics and predicting postoperative HPS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received no specific grants from funding agencies in the public, commercial, or non-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received approval from the Institutional Review Board (IRB) of Kobe University Hospital. The approval number for this study is #170024. In compliance with the ethical guidelines and regulations set by the IRB, written informed consent was obtained from all participants involved in this study. This process ensured that all participants were fully informed about the nature of the research, its objectives, and the use of the data collected, and their participation was voluntary.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the corresponding author.